Decitabine
Acute Myeloid Leukemia With Multilineage Dysplasia
National Cancer Institute (NCI)Small moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
32 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytarabine National Cancer Institute (NCI) | Phase 3 | BB |
Etoposide Institut de Recherches Internationales Servier | Phase 2 | BB |
Ivosidenib Institut de Recherches Internationales Servier | Phase 3 | BB |
Cyclophosphamide City of Hope Medical Center | Phase 3 | BB |
Fludarabine National Cancer Institute (NCI) | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Decitabine is also rated in:
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 4
72 / 100
View asset →acute myeloid leukemia with t(8;21)(q22;q22) translocationActive
BB
Indicative · Phase 3
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →